Teva Seeks To Draw A Line Under Opioids Litigation With Final US Settlement

State Sign-On Process Still To Play Out As Teva ‘Optimistic’ Of High Participation Rate

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.